Synthesis and application of fluorescent teixobactin analogs.

Michael A Morris, Chelsea R Jones, James S Nowick

Abstract read

In one paragraph

Article in Methods in enzymology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael A MorrisDepartment of Chemistry, University of California, Irvine, CA, United States.

Chelsea R JonesDepartment of Chemistry, University of California, Irvine, CA, United States.

James S NowickDepartment of Chemistry, University of California, Irvine, CA, United States; Department of Pharmaceutical Sciences, University of California, Irvine, CA, United States. Electronic address: jsnowick@uci.edu.

Funding

Development of Teixobactin AnaloguesR56AI137258 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI NOWICK, JAMES S · 2018 to 2018

$444k

NIAID NIH HHS R56 AI137258

6 · The paper itself

Abstract

Teixobactin is a promising new antibiotic that kills a spectrum of Gram-positive pathogens that are considered to be urgent threats by the CDC and the WHO. Better understanding of the novel mechanism of action of teixobactin may assist in developing new antibiotics and furthering our understanding of antibiotic resistance. This chapter describes the synthesis and application of fluorescent teixobactin analogs in fluorescence microscopy to study the mode of action of teixobactin. The first part of this chapter describes the synthesis and purification of fluorescent teixobactin analogs using two synthetic approaches. The second part of this chapter describes the application of the fluorescent teixobactin analogs to visualize their interactions with molecular targets in B. subtilis using fluorescence microscopy. The methods described herein provide synthetic access to chemical probes that may help further the understanding of antibiotic resistance.

Indexed as

DepsipeptidesAnti-Bacterial AgentsMicroscopy, FluorescenceAnti-Bacterial AgentsDepsipeptidesteixobactinAntibiotic resistanceAntibioticsBacteriaCell wallFluorescence microscopyFluorescent probesLipid IIMicrobiologySolid-phase peptide synthesisTeixobactin

Identifiers

PMID35379436

DOI10.1016/bs.mie.2021.12.006

PMCPMC9109785

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.